Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: Boddington who wrote (12773)	7/23/1999 2:08:00 PM
From: Boddington	Read Replies (1) \| Respond to of 52051

AVAN - details herein. quote.yahoo.com Currently #1 gainer with volume 33 times 65-day average. Chart suggests gap over the weekend. Especially likely if the news gets around. Good play at close? Definitely one to watch if their drug comes through. Any thoughts ? Recent headlines : Avant Immunotherapeutics Claims 89% Success For Rotavirus Vaccine, Dow Jones Online News, 07/23/1999, 11:49, 302 words New vaccine prevents childhood diarrhoea - study, Reuters, 07/23/1999, 00:31, 412 words New compound may help limit stroke damage - study, Reuters, 07/22/1999, 21:19, 684 words Clinical Results With AVANT Rotavirus Vaccine Demonstrate Nearly 90% Protection in Young Children, PR Newswire, 07/22/1999, 18:47, 1098 words AVANT'S Hybrid Complement-Selectin Inhibitor, TP20, Significantly Limits Brain Damage in an Animal Model of Ischemic Stroke, PR Newswire, 07/22/1999, 14:17, 1105 words AVANT Announces Novartis Exercise of Option to License TP10 in the Field of Transplantation, PR Newswire, 07/19/1999, 08:47, 940 words AVANT Immunotherapeutics Appoints Alistair Wheeler as Vice President, Medical Affairs, PR Newswire, 07/14/1999, 11:43, 755 words AVANT Achieves Major Milestone in Rotavirus Vaccine Program With SmithKline Beecham, PR Newswire, 06/21/1999, 09:44, 1044 words AVANT Begins Human Clinical Trials of Novel Atherosclerosis Vaccine, PR Newswire, 06/21/1999, 09:38, 770 words AVANT Immunotherapeutics Reports First Quarter 1999 Financial Results, PR Newswire, 05/13/1999, 14:01, 881 words